Science | 06 January 2025 | News
IIT Guwahati advances cholesterol and triglyceride detection with advanced nanotechnology
Researchers at Indian Institute of Technology Guwahati (IIT-G), led by Prof. Dipankar Bandyopad...Read more
Telangana | 31 December 2024 | Interviews
What key initiatives and strategic changes is the Telangana government implementing to attract investments in ...Read more
MedTech | 31 December 2024 | Views
India’s Transformative Leap in Medtech
AI-driven Diagnostics The application of artificial intelligence (AI) in healthcare has moved beyond experime...Read more
Uttar Pradesh | 06 January 2025 | News
Consint.AI raises Rs 5 Cr in seed round led by Equanimity Ventures & Seafund
GenAI driven healthcare Insurance fraud and risk management company Consint.AI has raised Rs 5 crore in a seed...Read more
Supplier | 17 December 2024 | News
New acquisition expands MilliporeSigma’s 2D and 3D cell culture portfolio
MilliporeSigma, the US and Canada Life Science business of Merck KGaA, Darmstadt, Germany, has announced that ...Read more
People | 18 December 2024 | News
Health tech startup Zyla Health on-boards Rohit Boda as Advisor
Gurugram-based Zyla Health, a care management platform, has announced the onboarding of renowned industry lead...Read more
Maharashtra | 23 December 2024 | News
IIT-B joins hands with Tohoku University to offer MTech and PhD dual degree programmes
The Indian Institute of Technology, Bombay (IIT-B) has entered into a Memorandum of Understanding (MoU) with J...Read more
Text blogs | 31 December 2024 | Views
Key Skills & Salary Trends in Healthcare & Pharma for 2025
Evolving Skillsets The healthcare and pharmaceutical industries are undergoing profound transformations...Read more
Indian Pharma Hits R&D Salvo
Pharma companies are constantly on the quest to discover the next big game-changer drug or therapeutic by leveraging the latest, cutting-edge innovation. While it is notable that biopharma companies eased up on their research and development (R&D) spending in FY 2022-23 after the world was hit by COVID-19- induced economic slowdown, the budget for R&D has witnessed a steady increase. Departing a bit from their traditional drug portfolios, companies are increasingly focusing on R&D in nextgeneration therapies to drive innovation, particularly in complex generics, biosimilars, cell and gene therapies and novel drug delivery systems.
For Feedback, please email us at: communications@mmactiv.com